Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma

<table>Kaplan-Meier survival curves for OS as determined by the levels of CCNY autoantibody. (a) All patients with nonsmall-cell lung cancer. (b) Postoperative patients with nonsmall cell lung cancer; (c) medical chemotherapy of patients with nonsmall cell-lung cancer.</table>

Disease Markers

fig4

Figure 4

Figure 4: Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma 

Figure 4 | Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma 